Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier
Years before the CAR-T therapies Kymriah and Yescarta hit the market, two French companies joined forces in a quest to bring off-the-shelf immunotherapies based on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
